纳武利尤单抗联合伊匹木单抗一线治疗晚期非小细胞肺癌(CheckMate 568):程序性死亡配体1与肿瘤突变负荷作为生物标志物的结局
CheckMate 568是一项开放标签II期试验,评估纳武利尤单抗联合低剂量伊匹木单抗一线治疗晚期/转移性非小细胞肺癌(NSCLC)的疗效与安全性。288例患者接受纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每6周治疗,总体客观缓解率(ORR)为30%,肿瘤PD-L1表达≥1%和<1%患者的ORR分别为41%和15%。肿瘤突变负荷(TMB)≥10个突变/兆碱基(mut/Mb)与更高的ORR和更长的无进展生存期相关。
要点
- 纳武利尤单抗联合低剂量伊匹木单抗一线治疗晚期/转移性NSCLC总体ORR为30%。
- PD-L1≥1%和<1%患者的ORR分别为41%和15%。
- TMB≥10 mut/Mb患者无论PD-L1表达如何,ORR均高于TMB<10 mut/Mb患者。
核心结论
- 纳武利尤单抗联合低剂量伊匹木单抗作为晚期/转移性NSCLC一线治疗有效且可耐受。
- TMB≥10 mut/Mb与肿瘤PD-L1表达≥1%和<1%两个亚组中更高的缓解率和更长的无进展生存期相关,因此被确定为评估TMB作为一线纳武利尤单抗联合伊匹木单抗生物标志物的潜在相关截断值。
研究设计与样本
- CheckMate 568是一项开放标签II期试验。
- 288例既往未治疗、复发IIIB/IV期NSCLC患者接受纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每6周治疗。
- 主要终点为肿瘤PD-L1表达≥1%和<1%患者的客观缓解率(ORR)。
- 基于TMB(FoundationOne CDx检测)的疗效为次要终点。
主要发现
- 在可评估PD-L1表达的患者中,288例中252例(88%)可评估;在可评估TMB的患者中,120例中98例(82%)可评估。
- 总体ORR为30%,肿瘤PD-L1表达≥1%和<1%患者的ORR分别为41%和15%。
- ORR随TMB升高而增加,在≥10 mut/Mb时达到平台。
- 无论PD-L1表达如何,TMB≥10 mut/Mb患者(n=48:PD-L1≥1%为48%;PD-L1<1%为47%)的ORR高于TMB<10 mut/Mb患者(n=50:PD-L1≥1%为18%;PD-L1<1%为5%)。
- TMB≥10 mut/Mb患者的中位无进展生存期为7.1个月,TMB<10 mut/Mb患者为2.6个月。
关键数值与推荐
- 肿瘤PD-L1表达≥1%患者ORR为41%,<1%患者ORR为15%。
- TMB≥10 mut/Mb且PD-L1≥1%患者ORR为48%(n=48),TMB≥10 mut/Mb且PD-L1<1%患者ORR为47%(n=48)。
- TMB<10 mut/Mb且PD-L1≥1%患者ORR为18%(n=50),TMB<10 mut/Mb且PD-L1<1%患者ORR为5%(n=50)。
- TMB≥10 mut/Mb患者中位无进展生存期为7.1个月,TMB<10 mut/Mb患者为2.6个月。
- 3至4级治疗相关不良事件发生率为29%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB). PATIENTS AND METHODS: Two hundred eighty-eight patients with previously untreated, recurrent stage IIIB/IV NSCLC received nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks. The primary end point was objective response rate (ORR) in patients with 1% or more and less than 1% tumor PD-L1 expression. Efficacy on the basis of TMB (FoundationOne CDx assay) was a secondary end point. RESULTS: Of treated patients with tumor available for testing, 252 patients (88%) of 288 were evaluable for PD-L1 expression and 98 patients (82%) of 120 for TMB. ORR was 30% overall and 41% and 15% in patients with 1% or greater and less than 1% tumor PD-L1 expression, respectively. ORR increased with higher TMB, plateauing at 10 or more mutations/megabase (mut/Mb). Regardless of PD-L1 expression, ORRs were higher in patients with TMB of 10 or more mut/Mb (n = 48: PD-L1, ≥ 1%, 48%; PD-L1, < 1%, 47%) versus TMB of fewer than 10 mut/Mb (n = 50: PD-L1, ≥ 1%, 18%; PD-L1, < 1%, 5%), and progression-free survival was longer in patients with TMB of 10 or more mut/Mb versus TMB of fewer than 10 mut/Mb (median, 7.1 v 2.6 months). Grade 3 to 4 treatment-related adverse events occurred in 29% of patients. CONCLUSION: Nivolumab plus low-dose ipilimumab was effective and tolerable as a first-line treatment of advanced/metastatic NSCLC. TMB of 10 or more mut/Mb was associated with improved response and prolonged progression-free survival in both tumor PD-L1 expression 1% or greater and less than 1% subgroups and was thus identified as a potentially relevant cutoff in the assessment of TMB as a biomarker for first-line nivolumab plus ipilimumab.
引用
- Ready N, Hellmann MD, Awad MM, et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. J Clin Oncol. 2019. PMID: 30785829. doi:10.1200/JCO.18.01042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。